Effect of adrenergic blocking agents on the vasopressin inhibiting action of norepinephrine.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D009638:Norepinephrine / Q000494:pharmacology*; D009994:Osmolar Concentration; D010643:Phenoxybenzamine / Q000494:pharmacology; D011188:Potassium / Q000652:urine; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D012964:Sodium / Q000652:urine; D013565:Sympatholytics / Q000494:pharmacology*; D014556:Urine / Q000032:analysis; D014667:Vasopressins / Q000037:antagonists & inhibitors*
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D013565:Sympatholytics; D010643:Phenoxybenzamine; D014667:Vasopressins; D012964:Sodium; D011433:Propranolol; D011188:Potassium; D009638:Norepinephrine